Doximity’s Q1 2027: Revenue Up, Margin Murmurs, and a 2027 Roadmap That Keeps AI on the Dial

DOCS — Doximity’s fiscal first quarter results land with a mix of steady top-line growth and margin pressure, set against a backdrop of aggressive AI initiatives and guidance that hints at higher spend in service of longer-term leverage.

Executive snapshot

In a quarter that many software-facing health-tech players would call “solid if you squint,” Doximity reports revenue of $156.6 million for the fiscal 2027 first quarter, up 7% year over year. GAAP net income came in at $24.3 million, yielding a net margin of 15.5% versus 36.5% a year earlier. On the earnings line, GAAP diluted EPS was $0.13, while non-GAAP diluted EPS stood at $0.29. Adjusted EBITDA totaled $74.8 million, with an EBITDA margin just under 48% (47.7%), down from 54.7% a year ago. In other words, the business is growing, but the levers that push profits higher are getting pulled in different directions.

In the language of the street, this is not a surprise so much as a data point in a longer conversation: revenue is stepping up, profitability per dollar of revenue is not keeping pace, and management is signaling sustained investment that could tilt the long-run cash-flow profile toward greater scale in AI-enabled products and features.

Financial highlights

Revenue: $156.6 million, up 7% year over year.
Net income: $24.3 million; net margin 15.5% (vs. 36.5% prior year).
EPS: Diluted GAAP EPS $0.13; non‑GAAP diluted EPS $0.29.
Adjusted EBITDA: $74.8 million; EBITDA margin 47.7% (vs. 54.7% prior year).
Cash flow: Operating cash flow $42.0 million; free cash flow $39.6 million (both down roughly one-third vs. year-ago levels).
Outlook: Q2 revenue guidance of $170–$171 million; Adjusted EBITDA guidance of $80.5–$81.5 million. For the full year ending March 31, 2027, revenue guidance is $671–$681 million; Adjusted EBITDA guidance $309–$329 million.
AI and product strategy: Doximity Ask achieved top-tier NOHARM benchmark credentials among U.S.-based models; AI Search query growth exceeds 25% quarter over quarter. Revenue mix and product initiatives are increasingly tied to AI-enabled workflows and prescriber engagement.

Analysis: what it portends for Doximity and its peers

Matt Levine would note the humor in a world where you can grow revenue by 7% while net income declines and the stock of burn-fueled optimism about AI remains the primary growth currency. The headline here is not a dramatic swing in top-line demand, but a deliberate shift in the operating equation: more revenue, less immediate margin leverage, and a clear plan to deploy cash toward higher-growth AI-enabled features and platform expansion.

On the profitability side, the decline in GAAP and Adjusted EBITDA margins signals either higher operating costs related to AI investments, go-to-market acceleration, or a combination of both. Management is guiding toward a Q2 growth cadence and a full-year outlook that implies continued investment, with revenue in the mid-$600s millions and Adjusted EBITDA in the low-to-mid $300s millions for the year. That’s a classic shift from near-term profitability to longer-term scale, especially when you pair it with AI-driven product momentum and a rising cadence of prescriber engagement.

Key questions for investors and peers: does the revenue forecast imply sustainable growth rate, or is the company paying up now for a larger, more defensible AI-enabled platform later? The absence of a disclosed EPS consensus in the release means analysts must fill the gap with models that incorporate higher R&D and go-to-market spend. If the market had penciled in stronger near-term net income or a higher EBITDA margin, the stock might have faced more pressure; instead, the combination of a higher revenue target and a still-strong cash-flow profile—relative to the quarter—could be read as a bet on efficiency gains as AI features scale.

From a sector view, Doximity’s AI investments mirror a broader arc in health-tech where data networks and physician-facing AI applications are converging with traditional employer and membership platforms. The company’s NOHARM benchmark recognition for its AI assistant and the double-digit growth in AI-related searches suggest a product moat forming around AI-enabled workflows. If Doximity can translate higher engagement and prescriber activity into durable usage-based revenue or high-margin subscription upsells, peers with similar AI bets might see a favorable spillover in valuation multiples—assuming users stay engaged and regulatory tailwinds remain supportive.

Outlook and implications for the sector

Guidance signals Q2 revenue in a narrow range around $170–$171 million and Adjusted EBITDA around $80.5–$81.5 million, with full-year revenue in the $671–$681 million band and Adjusted EBITDA in the $309–$329 million band. The numbers imply a continued mix of revenue growth alongside deliberate investment—likely higher operating expenses tied to AI initiatives, platform enhancements, and go-to-market energy. For peers, the takeaway is twofold: growth is increasingly paired with investment in AI-enabled productization, and the profitability path depends on whether those investments translate into higher incremental revenue and stickier, higher-margin usage over time.

As investors calibrate the durable-ness of this growth, a few near-term themes to watch across the sector emerge:

AI-driven product adoption and the ability to monetize AI-enabled features will be a primary determinant of future margins.
Cash flow generation remains a key compressor of multiple concerns; even with lower net income, strong operating cash flow and free cash flow provide cushion for continued investment without financing risk escalation.
EPS trajectory remains a function of mix and cost control; even with rising revenue, the path to a stable EPS figure may hinge on achieving higher gross margins and efficient scaling of AI workloads.

Takeaways

Revenue growth is solid but not explosive; EPS momentum is more muted as the company finances AI investments and platform expansion.
Margins are compressing on both GAAP and non-GAAP measures, reflecting higher investment postures that could pay off later if AI-enabled offerings gain material share.
The AI narrative remains the driver of longer-term earnings power, reinforced by strong AI benchmarks and user engagement metrics.
The forecasted revenue trajectory and cash-flow stability suggest Doximity can navigate the current cost environment while maintaining optionality for future upside from AI-enabled product adoption.
For sector peers, the message is: a robust user base and meaningful AI-enabled product features can coexist with near-term margin pressure if the cash-generating core remains intact.

Closing thoughts

In a climate where investors reward long-run monetization of AI-enabled platforms, Doximity’s Q1 results read as a measured step toward a more ambitious, AI-powered trajectory. The company is dialing up its revenue engine while laying the groundwork for stronger EBITDA leverage later, if the AI flywheel spins fast enough. For readers tracking the EPS trajectory, EPS consensus and earnings surprise will likely hinge on how quickly platform improvements translate into higher gross margins and a more compelling mix of revenue streams. In the meantime, DOCS remains a name to watch—not just for what it earned this quarter, but for what the AI-laden next chapters could unlock for it and its peers in health-tech.